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Gliomas comprise fewer than �% of malignant neo-
plasms �ut are argua�ly the deadliest and most difficult 
types of cancers to treat with current chemotherapeutic 
agents used clinically. The limited effectiveness of che-
motherapy during the treatment of gliomas� particularly 
glio�lastomas� is largely due to permea�ility restrictions 
imposed �y the �lood �rain �arrier present in the �rain as 
well as the activation of intracellular cytoprotective path-
ways that antagonize the effects of chemotherapeutic 
agents used to treat this disease. It has therefore �ecome 
imperative to examine novel agents and approaches that 
might overcome the limitations of current chemotherapy 
regimens used to treat glio�lastomas clinically.
Microtu�ules are cytoskeletal proteins formed from 
heterodimers of alpha �α� and �eta �β� tu�ulin that 
primarily function to provide structure and sta�ility in 
eucaryotic cells important for mitotic spindle formation 
during cell division and vesicular and organelle transport. 
These cellular processes are governed �y the dynamic 
insta�ility of microtu�ule polymerization and depolymer-
ization� characterized �y microtu�ule nucleation at the 
microtu�ule-organizing center and guanine triphosphate 
hydrolysis� respectively [�]. The kinetic changes of micro-
tu�ules� �etween assem�ly and disassem�ly have made 
them primary targets in the experimental investigation 
and clinical treatment of many human cancers [�].
Clinically� three classes of microtu�ule inhi�itory 
agents that induce positive anti-tumorigenic responses 
have primarily �een used to treat human cancers� the 
vinca alkaloids� colchicines� and taxanes [�]. However� 
the clinical effectiveness of these compounds is ac-
companied �y harmful side effects and is limited �y the 
activity of P-glycoprotein �P-gp�� an energy dependent 
drug efflux transporter protein that plays an intricate role 
in the resistance of cancer cells to chemotherapeutic 
agents [�]. These clinical caveats have made it neces-
sary to investigate the utility of new microtu�ule inhi�i-
ting agents that circumvent mechanisms contri�uting 
to the resistance of human cancers.
In the current study� we investigated the anti-tumori-
genic effects of the contemporary microtu�ule inhi�iting 
agent� epothilone B in glio�lastoma cells using clinically 
achieva�le concentrations. Epothilones are microtu�ule-
sta�ilizing agents isolated from the myxo�acterium 
Sorangium cellulosum [4] and have �een shown to �e 
effective microtu�ule inhi�itory agents in clinical and 
experimental studies of human cancers such as �reast� 
prostate� ovarian� and lung cancer [��7]. Epothilones are 
proving to �e practical alternatives to classic taxanes �ie 
paclitaxel� historically used as chemotherapeutic agents 
in the treatment of several human cancers. This is due 
in large part to the high water solu�ility of epothilones 
and their a�ility to inhi�it the growth of cancer cells 
overexpressing the P-gp efflux pump [�]. Additionally� we 
assessed the involvement of the anti-apoptotic protein� 
survivin in epothilone B treated glio�lastoma cells.
MATERIALS AND METHODS
Cells conditions and reagents. T��� LNZ� and U�7 
glio�lastoma cells were purchased from the American 
Type Culture Collection �Manassas� VA-U�A�. All cell lines 
were maintained in Dul�ecco’s Modified Eagles Medium-
DMEM �Invitrogen� Carls�ad� CA-U�A� containing ��% 
Fetal Bovine �erum �Invitrogen�� � mM L-glutamine 
�Invitrogen�� ��� nM MEM non-essential amino acids 
�Invitrogen�� and penicillin-streptomycin �Invitrogen� at 
�7 °C and �% CO�. Epothilone B was purchased from 
EMD-Cal�iochem Biosciences ��an Diego� CA-U�A�.
Crystal violet cell proliferation assay. Dose re-
sponse experiments were performed using a modification 
of the crystal violet assay [��]. Cells were plated in �4 well 
plates for twenty-four hours� treated with � nM� � nM� and 
�� nM epothilone B �vehicle controls were treated with 
DM�O ��igma-Aldrich� �t. Louis� MO-U�A� and allowed 
to incu�ate for 4� h. Next tissue culture medium was 
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removed; the cell monolayer was fixed with ���% metha-
nol for � min and stained with �.�% crystal violet in ��% 
methanol for �� min. Cells were then washed three times 
five minutes each with distilled water to remove excess 
dye and allowed to dry overnight at room temperature. 
The incorporated dye was then solu�ilized in �.� M sodium 
citrate ��igma-Aldrich� in ��% ethanol. Next� ��� µl of 
treated and control samples were transferred to �6 well 
plates and optical densities read at �4� nm using a Biorad 
6�� microplate reader �BioRad� Hercules� CA-U�A�.
Determination of viable cell number by trypan 
blue dye exclusion. Cells were plated for �4 h� treated 
with �� nM epothilone B �EMD-Cal�iochem� and al-
lowed to incu�ate for �� �� 4� and � days at �7 °C. At the 
end of each time point� cells were trypsinized from a 
monolayer culture with �.��% trypsin-EDTA �Invitro-
gen�� centrifuged� and resuspended in media or PB�. 
Next� �� µl of cell suspension were mixed with �� µl of 
trypan �lue and counted using a hemacytometer.
Western blotting. Cells were plated in DMEM con-
taining ��% FB� for twenty-four hours� treated with �� nM 
epothilone B �EMD-Cal�iochem�� and allowed to incu�ate 
for �4� 4�� and 7� h. Cells were lysed in lysis �uffer �pH 6.�� 
containing 6� mM Tris and �% �D�. Protein concen-
trations were determined using the Bradford Method. 
�amples were electrophoresed in a ��% polyacrylamide 
gel� transferred to nitrocellulose mem�ranes and immu-
no�lotted with a polyclonal anti�ody against tu�ulin �Cell 
�ignaling� Danvers� MA-U�A�. �ignals were detected 
using a horseradish peroxidase conjugated secondary 
anti�ody and colorimetric detection system �BioRad�.
ELISA. Cells were plated for twenty-four hours� 
treated with �� nM epotholine B �EMD-Cal�iochem� �an 
Diego� CA-U�A� and allowed to incu�ate two and four 
hours. Next cells were fixed in 4% paraformaldehyde for 
� min� rinsed with PB�� permea�ilized in �.�7�% triton 
X-��� /PB� for � minutes and rinsed again with PB�. Cells 
were then �locked in PB� containing �% �ovine serum 
al�umin ��igma� and �.�% horse serum �VectorLa�s� 
Burlingame� CA-U�A� for one hour at room temperature. 
�amples were then incu�ated with a primary anti�ody 
against survivin �Cell �ignaling� for twenty-four hours at 
4 °C. �u�sequently� cells were rinsed with PB�� incu�ated 
with a horseradish peroxidase conjugated secondary 
anti�ody for one hour� and rinsed again. Next� cells were 
treated with TMB peroxidase su�strate �BioRad� for five 
minutes and optical densities read at 6�� nm.
Clonogenic survival. Cells were plated for twenty-
four hours� treated with � nM� ��� pM epothilone B 
�EMD-Cal�iochem�� or DM�O �vehicle� and allowed 
to incu�ate at �7 °C for ����4 days. At the termination 
of the incu�ation period� cells were fixed with a�solute 
methanol� stained with �% crystal violet for �� min� 
rinsed in tap water and allowed to dry. Colonies� consist-
ing of > �� cells� were then counted to determine surviv-
ing fraction. �urviving fraction ��F� was determined as 
follows: �F = num�er of colonies counted/num�er of 
cells plated x plating efficiency.
Acridine orange labeling. Cells were plated for 
twenty-four hours� treated with epothilone B ��� nM� 
or DM�O �vehicle� and allowed to incu�ate for 7� h. 
Following epothilone B treatment cells were incu�ated 
with media containing ��� ng/ml acridine orange 
�Molecular Pro�es�Invitrogen� Carls�ad� CA-U�A� for 
�� min. Acridine orange was removed and images were 
captured using an Olympus IX-�� �Olympus�Center Val-
ley� PA-U�A� fluorescent microscope.
Immunofluorescence labeling. Cells were plated 
and allowed to attach for �4 h in �� well plates. Cells were 
then treated with epothilone B ��� nM and �� nM� or ve-
hicle �DM�O� for six hours� rinsed in PB�� and fixed in 4% 
paraformaldehyde for � min at room temperature. Cells 
were then rinsed with PB� post-fixation� permea�ilized in 
�.�7�% Triton-X ���/PB� for five minutes� rinsed again� 
and �locked with �.�% �ovine serum al�umin� �.�% horse 
serum �VectorLa�s� in PB� for � h at room tempera-
ture. Cells were next incu�ated overnight at 4 °C with an 
α-tu�ulin �Molecular Pro�es-Invitrogen� anti�ody in �% 
B�A/PB�. �amples were next rinsed three times with PB�� 
incu�ated with an Alexa 4�� goat-anti-mouse conjugated 
secondary anti�ody �Molecular Pro�es-Invitrogen� for � h 
in the dark� rinsed again and examined with an Olympus 
IX-�� �Olympus� fluorescent microscope.
Statistical analysis. �tudent’s �t� test and one 
way Analysis of Variance statistical analysis were per-
formed to convey significance relating to cell num�er 
and protein levels.
RESULTS
Dose response of glioblastoma cells to epothi-
lone B. To assess the efficacy of epothilone B� T�� �p�� 
mutant�� U�7 �p�� wild-type�� and LNZ �p�� null� glio-
�lastoma cells were treated with � nM� � nM� and �� nM 
epothilone B for 4� h �Fig. ��. Data revealed a dose 
dependent decrease in cell proliferation of T��� U�7� 
and LNZ glio�lastoma cells treated with epothilone B. 
Exposure of cells to �� nM epothilone B demonstrated a 
��% and �4% reduction �p < �.��� in cell proliferation of 
T�� �p�� mutant� and LNZ �p�� null� glio�lastoma cells� 
respectively� as compared to vehicle treated controls 
�see Fig. ��. In contrast U�7 �p�� wild type� glio�lastoma 
cells exposed to epothilone B ��� nM� showed only a 
minor decrease that was not significant �p > �.���� as 
determined �y student �t� test.
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Fig. 1. Dose response experiments of epothilone B treated glio-
�lastoma �T��� LNZ� U�7� cells. Vehicle treated control cells �solid 
white �ars�; � nM epothilone B �solid �lack �ars�; � nM epothilone 
B �hatched white �ars�; �� nM epothilone B �speckled �lack �ars�. 
Data shown are representative of three independent experiments 
�means ± �E� performed in duplicate showing similar results 
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Time course analysis. To further examine the uti lity 
of epothilone B� time course experiments were performed 
over a five day time period on glio�lastoma cells treated 
with �� nM epothilone B �Fig. ��. Time course analysis 
showed a reduction in total cell num�er of T�� �p�� mu-
tant� cells� in response to epotholine B ��� nM� exposure� 
at each time point examined as compared to vehicle 
treated control cells at the same time point over the five 
day time course� as determined �y trypan �lue dye ex-
clusion. Additionally� we o�served a significant �p < �.��� 
decline in epothilone B ��� nM� treated T�� �p�� mutant� 
cells over the five day time period as determined �y 
ANOVA analysis� with a 7�% reduction in total cell num�er 
o�served �etween day � and day � �see Fig. ��. These 
data parallel several experimental studies in prostate [6� 
�]� �reast [�]� and ovarian [��] cancer that also demon-
strated the cytotoxic effects of epothilone B.
0
20
40
60
80
100
120
140
1 2 3 4 5 6
Time points (hours)
# 
of
 c
el
ls
 x
 1
04
Control
Epothilone B
LNZ
0
20
40
60
80
100
1 2 3 4 5 6
Time point (hours)
# 
of
 c
el
ls
 x
 1
04
Epothilon
Control
T98
0
2
4
6
8
10
12
1 2 3 4 5 6
Time point (hours)
# 
of
 c
el
ls
 x
 1
04 Control
Epothilone 
U87
Fig. 2. Time course analysis of glio�lastoma cells treated with 
epothilone B ��� nM� or DM�O �vehicle control�. Top: T�� �p�� 
mutant� glio�lastoma cells Middle: LNZ �p�� null� glio�lastoma 
cells. Bottom: U�7 �p�� wild type� glio�lastoma cells. Data 
shown are representative of three independent experiments 
�means ± �E� performed in duplicate displaying similar results
Consistent with time course analysis in T�� �p�� 
mutant� glio�lastoma cells� epothilone B ��� nM� also 
inhi�ited proliferative capacity in LNZ �p�� null� glio-
�lastoma cells� due to a prolonged growth arrest� over 
the five day time period as compared to vehicle treated 
control cells �see Fig. ��. However� in U�7 �p�� wild 
type� glio�lastoma cells time course data displayed a 
transient growth arrest post-epothilone B treatment� 
followed �y a pronounced proliferative recovery� where 
a ��% increase in total cell num�er was o�served on 
day 4 as compared to day � �see Fig. ��. Taken together 
these data suggest that epothilone B induced p�� 
independent cytotoxic and cytostatic responses in 
glio�lastoma cells� supporting studies conducted �y 
Vikhanskaya et al. ������ [��] and Bacus et al. ������ 
[��] who showed microtu�ule inhi�iting agents induce 
p��-independent anti-tumorigenic effects in ovarian 
and �reast cancer cells� respectively.
Epothilone B effects on reproductive capacity. 
In addition to time course analysis� clonogenic survival 
experiments were performed to assess the a�ility of 
epothilone B to inhi�it reproductive capacity of glio-
�lastoma cells exposed to a non-toxic concentration 
�Fig. ��. We o�served 47% and ��% fewer colonies 
�p < �.��� in epothilone B ���� pM� treated T�� and 
LNZ glio�lastoma cells� respectively� as compared to 
vehicle treated controls. Clonogenic survival data also 
revealed� like T�� and LNZ cells� U�7 glio�lastoma 
cells had a reduced reproductive capacity in response 
to epothilone B as compared to vehicle controls. How-
ever no significant �p > �.��� difference was o�served 
�etween untreated U�7 cells �data not shown� and U�7 
cells treated with epothilone B� in contrast to T�� and 
LNZ cells �data not shown�. Furthermore� crystal violet 
staining �Fig. 4� displayed a complete a�rogation of T�� 
and LNZ glio�lastoma cell colony formation when treat-
ed with � nM epothilone B� as compared to untreated 
and vehicle treated control cells. In contrast treatment 
of U�7 glio�lastoma cells with � nM epothilone B did not 
completely inhi�it colony formation �see Fig. 4�.
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Fig. 3. Clonogenic survival of glio�lastoma cells treated with epothi-
lone B for 7� h. Vehicle control �white �ars�; ��� pM epothilone B 
��lack �ars�. Data shown are representative of at least three inde-
pendent experiments �means ± �E� with compara�le results
Additionally� in effort to determine the mode of 
glio�lastoma cell death as a consequence of epothi-
lone B exposure we used acridine orange la�eling to 
assess autophagy or type II cell death. Fluorescent 
la�eling experiments with acridine orange did not 
detect cytoplasmic autophagic vacuoles charac-
teristic of autophagic cell death. Instead acridine 
orange la�eling revealed the presence of fragmented 
DNA and apoptotic cell �odies in T��� LNZ� and U�7 
��� Experimental Oncology ��� �������� ���� ��eptem�er�
glio�lastoma cells �Fig. ��� 7� h post-treatment with 
�� nM epothilone B. Consistent with results seen here 
Moo�erry et al. ������ [��] also o�served induced 
DNA fragmentation in aortic smooth muscle cells in 
response to treatment with the contemporary micro-
tu�ule sta�ilizing agent� laulimalide [��].
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Fig. 4. Crystal violet staining of T�� �a–c�� LNZ �d–f�� and U�7 
�g–i� glio�lastoma cells treated with � nM epothilone B. Cells 
shown are of a single colony from a clonogenic survival experiment 
performed in duplicate that is representative of three independent 
experiments showing similar results �scale �ar = �� µm�
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Fig. 5. Acridine orange la�eling in glio�lastoma cells treated 
with �� nM epothilone B for 7� h. a–c: T��; d–f: LNZ; g–i: U�7. 
Data shown are representative of four independent experiments 
displaying compara�le results �scale �ar = �6� µm�
Epothilone B induced effects on tubulin. Epothi-
lone B is a microtu�ule-sta�ilizing agent that exerts its 
effects �y �inding to tu�ulin� an α/β heterodimer com-
plex of microtu�ules. We therefore assessed tu�ulin 
protein levels in glio�lastoma cells treated with �� nM 
epothilone B over seventy-two hours. Time course 
protein analysis using immuno�lotting procedures 
revealed no change in the overall levels of tu�ulin as 
a consequence of epothilone B treatment �Fig. 6�. To 
further assess the effects of epothilone B on tu�ulin 
in glio�lastoma cells immunofluorescent experiments 
were conducted. Immunola�eling studies revealed 
the presence of an extended filamentous array of 
α-tu�ulin in control glio�lastoma cells� while a more 
perinuclear localization and considera�le reduction 
of filamentous α-tu�ulin was o�served in epothilone B 
treated T��� LNZ� and U�7 glio�lastoma cells �Fig. 7�. 
These changes in the organization of α-tu�ulin parallel 
those seen �y Dietzmann et al. ������ [�4] in LN4�� 
glioma cells treated with epothilone D.
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Fig. 6. Time course analysis of tu�ulin expression in glio�lastoma 
cells exposed to �� nM epothilone B. Lane: ��� vehicle control� 
��� �4 h� ��� 4� h� �4� 7� h. Results shown are representative of 
three independent experiments that displayed similar results
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Fig. 7. Immunofluorescence la�eling of α-tu�ulin in epothilone B 
��� nM� treated glio�lastoma cells at six hours. T�� cells �a–c�; LNZ 
cells �d–f�; U�7 �g–i�. Arrows: cytoplasmic expression of α-tu�ulin; 
Arrowheads: α-tu�ulin expressed at the periphery of the nucleus. 
�hown are tu�ulin expressing cells o�served from at least three 
areas of an experiment representative of at least three independent 
studies exhi�iting similar results �scale �ar = �6� µm�
Survivin expression in response to epothi-
lone B. In a further effort to assess the mechanistic 
�asis underlying cellular responses in epothilone 
B treated glio�lastoma cells �T��� LNZ� U�7�� we 
exa mined survivin levels� a known mitotic regulator 
and anti-apoptotic protein [��]� in glio�lastomas 
[�6]. ELI�A experiments revealed a time dependent 
decrease of survivin in T�� cells post-epothilone B 
��� nM� exposure as compared to vehicle treated 
control cells� with a ��% �p < �.��� decrease o�served 
at 6 h �Fig. ��. However LNZ cells showed a 6�% and 
��% �p < �.��� increase of survivin at � and 4 h� re-
spectively� post-epothilone B ��� nM� treatment as 
compared to vehicle treated controls. Epothilone B 
treated U�7 cells displayed no significant �p > �.��� 
changes in survivin levels when compared to vehicle 
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controls �Fig. ��. These data are consistent with stu-
dies performed �y Griffin et al. ������ [��] and Wang 
et al. ������ [�7]� who similarly showed a reduction 
of survivin in ovarian cancer cells after treatment with 
the microtu�ule inhi�iting agents BM�-�47���� an 
epothilone B analogue� and taxol� respectively.
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Fig. 8. �urvivin expression in glio�lastoma cells treated with 
�� nM epothilone B. Vehicle controls �white �ars�; �� nM epothi-
lone B ��lack �ars�. Data shown are representative of three 
independent experiments �means ± �E� performed in duplicate 
displaying compara�le results
DISCUSSION
The clinical resistance of glio�lastomas to che-
motherapeutic drugs� particularly classic microtu�ule 
inhi�iting agents �vincristine� paclitaxel�� is well docu-
mented [��]. The present study was undertaken to as-
sess the efficacy of the contemporary microtu�ule sta-
�ilizing agent epothilone B on glio�lastoma cells. Data 
here has shown that a clinically relevant concentration 
of epothilone B induced growth arrest in glio�lastoma 
cells� a result consistent with the primary mode of ac-
tion of microtu�ule targeting agents. Additionally� we 
o�served the promotion of glio�lastoma cell death 
with epothilone B� a response often o�served as a 
su�sequent event to mitotic growth arrest in tumor 
cells exposed to microtu�ule inhi�iting agents. These 
findings parallel previous preclinical investigations �y 
Yoshida et al. ������ [��] and Dietzmann et al. ������ 
[�4] that also demonstrated anti-neoplastic effects 
with the microtu�ule targeting agents estramustine 
and epothilone D on glio�lastoma cells� respectively. 
Furthermore� data here extends previous o�servations 
of microtu�ule inhi�iting agents on glio�lastomas �y 
providing evidence on the involvement of survivin and 
p�� in the tumor cell response of this neoplasm.
Microtu�ule inhi�iting agents exert their anti-tumori-
genic effects on cancer cells �y inhi�iting microtu�ule 
dynamics and function. We therefore examined changes 
in alpha-tu�ulin� a component of the microtu�ule he-
terodimeric complex. We o�served reduced filametous 
alpha-tu�ulin� representative of a disrupted microtu�ule 
network� in epothilone B treated glio�lastoma cells. 
These data provide evidence that epothilone B induced 
changes of tu�ulin in glio�lastoma cells are involved in 
our o�served cytostatic response. Furthermore these 
data suggest that changes in the microtu�ule network 
play a role in the cytotoxic response of glio�lastoma 
cells treated with epothilone B� changes similarly seen in 
aortic smooth muscle cells� lung cancer cells� and leu-
kemia cells that also underwent cell death in response 
to microtu�ule targeting agents [��� ��]. 
Due to our o�servation that epothilone B induced 
glio�lastoma cell death was not preceded �y mitotic 
growth arrest and the lack of experimental evidence 
regarding a direct role of tu�ulin in drug induced cell 
death we examined the role of the anti-apoptotic 
protein� survivin. In addition to survivin’s role as an 
anti-apoptotic protein� it is also a mitotic regulator 
of cell division as a component of the chromosome 
passenger complex �Aurora B and Inner Centromere 
Protein� at kinetochores� which functions to ensure 
proper chromosome and microtu�ule spindle associa-
tion [��]. �urvivin has �een shown to co-localize with 
microtu�ules [��� ��] and inhi�iting its function has 
�een shown to promote malformations in microtu�ule 
assem�ly [��]. Additionally� it has �een shown that 
glio�lastomas express survivin and contri�utes to the 
clinical resistance of this neoplasm to therapy [�6]. 
In light of survivin’s expression in glio�lastomas and 
its role as a pro-survival protein and mitotic regulator 
we examined survivin levels in epothilone B treated 
glio�lastoma cells in the current study. We o�served 
a down-regulation of survivin in epothilone B treated 
p�� mutant glio�lastoma cells; paralleling results in 
ovarian cancer cells treated with the epothilone B de-
rivative� BM� �47��� [��] and taxol [�7]. Furthermore� 
we o�served an increase of survivin expression in p�� 
null glio�lastoma cells that underwent growth arrest 
post-epothilone B exposure� a response also seen in 
taxol treated �reast and cervical carcinoma cells [��� 
�6]. Collectively these data suggest that epothilone 
B induces glio�lastoma cell death via apoptosis. This 
was further supported in the present study �y the 
presence of fragmented DNA and apoptotic cells �o-
dies with a marker for autophagy or type II cell death. 
In support of our findings Li et al. ����7� [�7] also 
detected fragmented chromatin and apoptotic cell 
�odies with the autophagic marker� acridine orange� 
in epidermoid carcinoma cells treated with oridonin. 
The identification of apoptotic cells with a marker for 
autophagy in the present study can in part �e explained 
�y an esta�lished relationship �etween autophagy 
and apoptosis. Although the mechanism underlying 
the synergistic relationship �etween autophagy and 
apoptosis are not clear it is esta�lished that autophagy 
precedes apoptosis during this cooperative mode of 
cell death [��]. This sequential mode of cell death 
has �een descri�ed experimentally in oridonin treated 
�reast cancer cells [��] and lysosome asscociated 
mem�rane protein �LAMP� depleted Hela cells [��]. 
The detection of fragmented DNA and apoptotic cell 
�odies with acridine orange la�eling descri�ed here 
suggests that this sequential mode of cell death is 
occurring during epothilone B induced glio�lastoma 
cell death. It should also �e stated that the presence 
of fragmented chromatin and apoptotic cell �odies in 
p�� null and wild-type glio�lastomas cells suggest that 
a small su�poplation of these cells were sensitive to 
��� Experimental Oncology ��� �������� ���� ��eptem�er�
drug treatments. Taken together these data support 
a pro-survival role for survivin in glio�lastoma cells� 
which is likely due to survivin’s function in microtu�ule 
and chromosome sta�ility. However� it should also 
�e mentioned that studies in �reast tumor cells have 
identified cytoprotective functions of mitochondria 
localized survivin [��]� a pool of survivin that may also 
�e contri�uting to epothilone B treated glio�lastoma 
cell responses o�served here.
Furthermore� we have shown here that epotholine B 
invokes an anti-tumorigenic response in glio�lastoma 
cells with a�errant p�� expression with limited utility in 
p�� wild-type glio�lastoma cells. These findings are 
consistent with the well esta�lished utility of the classic 
microtu�ule sta�ilizing agent� taxol� which has �een 
shown in several studies to efficiently induce cell kill in 
tumor cells with deficient p�� [��� ��]. Taken together 
data from this study provide preclinical evidence for 
the use of epothilone B and its analogues in the treat-
ment of primary and secondary glio�lastomas with 
p�� mutations present in approximately ��% and 6�%� 
respectively� of these high-grade gliomas [��� �4]. 
Additionally� therapeutic agents specifically targeting 
tumor cells� particularly glio�lastomas� with a�normal 
p�� have strong clinical promise due to their a�ility to 
spare normal cells. Future studies from our la�oratory 
will examine further the relationship of p�� and survivin 
in glio�lastomas treated with novel microtu�ule inhi�it-
ing agents� as the functional loss of p�� has �een as-
sociated with survivin up-regulation [��]. Epotholine 
B� is a via�le alternative to current taxanes and vinca 
alkaloids used in adjuvant and neoadjuvant approaches 
for the clinical treatment of glio�lastomas.
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ЭПОТИЛОН B ВЫЗЫВАЕТ ГИБЕЛЬ КЛЕТОК ГЛИОБЛАСТОМЫ 
ПУТЕМ СНИЖЕНИЯ УРОВНЯ ЭКСПРЕССИИ СУРВИВИНА 
Клиническая резистентность глиобластом к химиотерапии может быть объяснена действием насосов, откачивающих пре-
параты, подобные P-гликопротеину, которые играют важную роль в снижении эффективности лекарственных средств. 
Цель: изучить возможность применения эпотилона В, не являющегося субстратом для Р-гликопротеина, для воздействия 
на глиобластомные клетки. Методы: для оценки эффективности эпотилона В как антинеопластического препарата в ра-
боте in vitro использованы клеточные линии глиобластомы, отличающиеся по статусу p53. Для оценки уровня экспрессии 
тубулина и сурвивина в клетках, обработанных эпотилоном В, были использованы методы иммунофлуоресценции и ELISA. 
Окрашивание акридиновым оранжевым применяли для детекции погибших клеток после обработки эпотилоном В. Резуль-
таты: клинически достижимые концентрации эпотилона В оказывали цитотоксический ответ на клетки глиобластомы с 
мутантным р53 в результате снижения уровня сурвивина и перераспределения тубулина. В то же время цитостатический 
эффект наблюдали и на клетках глиобластомы, не экспрессирующих р53, что сопровождалось небольшим повышнием 
экпрессии сурвивина после обработки клеток эпотилоном В. Однако на клетках глиобластомы с р53 дикого типа не было 
выявлено антиопухолевого ответа на эпотилон В. Выводы: эпотилон В вызывает различный противоопухолевый ответ 
в клетках глиобластомы, экспрессирующих мутантный р53, либо отрицательных по р53. Это позволяет предположить, что 
эпотилон В является альтернативой классическим препаратам, ингибирующим микротрубочки (например винкристину, 
паклитакселу), которые используют в клинической практике при лечении глиобластом с мутантным белком р53. 
Ключевые слова: глиобластома, эпотилон В, сурвивин, белок p53.
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